Lista de obras -

18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.

artículo científico publicado en 2010

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

artículo científico publicado en 2010

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2013

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

artículo científico publicado en 2008

A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival.

artículo científico publicado en 2005

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

artículo científico publicado en 2014

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

artículo científico publicado en 2013

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

artículo científico publicado en 2019

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

scientific article published on June 2008

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

artículo científico publicado en 2015

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

artículo científico publicado en 2019

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

artículo científico publicado en 2017

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

artículo científico publicado en 2020

Bowel perforation in intestinal lymphoma: incidence and clinical features.

artículo científico publicado en 2013

Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas

artículo científico publicado en 2005

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

artículo científico publicado en 2017

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

scientific article published on 11 March 2019

Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study

artículo científico publicado en 2009

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

artículo científico publicado en 2013

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

artículo científico publicado en 2018

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

artículo científico publicado en 2014

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

artículo científico publicado en 2017

Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

artículo científico publicado en 2020

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma ⬇️

artículo científico publicado el 7 de marzo de 2011

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

artículo científico publicado en 2012

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation ⬇️

artículo científico publicado el 8 de febrero de 2012

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

artículo científico publicado en 2011

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

artículo científico publicado en 2014

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

artículo científico publicado en 2014

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

artículo científico publicado en 2011

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

artículo científico publicado en 2014

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

artículo científico publicado en 2017

Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

artículo científico publicado en 2010

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

artículo científico publicado en 2012

FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.

artículo científico publicado en 2013

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.

artículo científico

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

artículo científico publicado en 2014

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities

artículo científico publicado en 2012

Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma ⬇️

artículo científico publicado el 20 de junio de 2012

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

scientific article published on 13 January 2020

History of autoimmune conditions and lymphoma prognosis

scientific article published on 01 August 2018

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

artículo científico publicado en 2019

Human Pegivirus infection and lymphoma risk and prognosis: a North American study

artículo científico publicado en 2018

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

artículo científico publicado en 2009

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

scientific article published on 01 October 2019

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

artículo científico publicado en 2019

Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999

artículo científico publicado en 2002

Inherited determinants of ovarian cancer survival

artículo científico publicado en 2010

Inherited variants in regulatory T cell genes and outcome of ovarian cancer

artículo científico publicado en 2013

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

artículo científico publicado en 2014

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

scientific article published on 01 March 2020

Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma

artículo científico publicado en 2018

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

artículo científico publicado en 2008

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

artículo científico publicado en 2018

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas ⬇️

artículo científico publicado el 3 de noviembre de 2011

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

artículo científico publicado en 2014

POD24 in MZL: a means to an end or an end point in itself?

scientific article published on 01 September 2019

PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data.

artículo científico publicado en 2014

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

artículo científico publicado en 2005

Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

artículo científico publicado en 2005

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes

artículo científico publicado en 2017

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

scientific article published on 14 November 2019

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study

artículo científico publicado en 2012

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

artículo científico publicado en 2005

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

artículo científico publicado en 2018

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma

scientific article published on 18 October 2013

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

artículo científico publicado en 2018

Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

artículo científico publicado en 2006

Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients

artículo científico publicado en 2006

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

artículo científico publicado en 2015

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

artículo científico publicado en 2015

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

artículo científico publicado en 2020

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

artículo científico publicado en 2009

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

artículo científico publicado en 2020

Testicular FDG-PET/CT Uptake Threshold in Aggressive Lymphomas

artículo científico publicado en 2020

The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer

artículo científico publicado en 2020

The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma

artículo científico publicado en 2012

The association of health behaviors with quality of life in lymphoma survivors

artículo científico publicado en 2020

The potential of serum light chains in diffuse large B-cell lymphoma

artículo científico publicado en 2013

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

artículo científico publicado en 2013

The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas

artículo científico publicado en 2019

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

artículo científico publicado en 2014

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

artículo científico publicado en 2014

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

artículo científico publicado en 2010

Lista de obras de

18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival.

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

Bowel perforation in intestinal lymphoma: incidence and clinical features.

Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma ⬇️

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation ⬇️

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.

Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities

Germline variation in complement genes and event‐free survival in follicular and diffuse large B‐cell lymphoma ⬇️

High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?

History of autoimmune conditions and lymphoma prognosis

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

Human Pegivirus infection and lymphoma risk and prognosis: a North American study

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999

Inherited determinants of ovarian cancer survival

Inherited variants in regulatory T cell genes and outcome of ovarian cancer

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas ⬇️

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

POD24 in MZL: a means to an end or an end point in itself?

PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data.

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes

Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

Testicular FDG-PET/CT Uptake Threshold in Aggressive Lymphomas